If you are having trouble viewing this email, click here
Boston BioFlash

Sponsored by

June 28, 2016

​Why Sarepta just made its soon-to-begin drug trial even longer

Sarepta lengthened the duration of the placebo-controlled ESSENCE trial from one year to two. And that’s not making patient advocates happy.

 

​Infinity Pharma lays off another 100 after AbbVie ends partnership

The Cambridge drug company has cut two-thirds of its staff in the past two weeks after trial results of its blood cancer drug were said to be disappointing.

 

Medtronic bids $1.1B to buy Framingham's HeartWare

The deal would nearly double HeartWare’s market value as of Friday.

 

​Another Mass. biotech plans to take the IPO plunge despite Brexit uncertainty

Cambridge-based Syros has proposed an initial public offering of about $60 million.

 

PureTech launches startup to analyze voice samples for signs of disease

​With Selecta, total raised by Mass. biotechs so far this year hits $376M

Boston Business Journal Science & Tech Newsletters

Don Seiffert

Life Sciences Editor

dseiffert@bizjournals.com

617-316-3271

Connect with us

News from the BBJ

National Technology News

Fast-growing ABQ biotech startup acquired for $90 million in cash

'Brexit' not expected to hurt Cempra's EU drug application

Y Combinator seeks proposals to build a better city

Cancel Email Subscription

You may change your email address, your preferences, or unsubscribe from this email at any time by visiting bizjournals.com: https://www.bizjournals.com/account/

If you need other assistance, please let us know or contact: bizjournals.com customer service, bizjournals 120 W. Morehead St., Charlotte, North Carolina 28202

The Business Journals | Latest News | Advertise | Contact Info | Subscribe to Print Edition

© 2016 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this may not be reproduced, distributed, transmitted, cached or otherwise used, except with the written permission of bizjournals.